Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions

The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has...

Descripción completa

Detalles Bibliográficos
Autores principales: Ridruejo, Ezequiel, Pereson, Matías Javier, Flichman, Diego M, Di Lello, Federico Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473504/
https://www.ncbi.nlm.nih.gov/pubmed/34630875
http://dx.doi.org/10.4254/wjh.v13.i9.1069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473504/
https://www.ncbi.nlm.nih.gov/pubmed/34630875
http://dx.doi.org/10.4254/wjh.v13.i9.1069

Ejemplares similares